Skip to Content
Merck
CN
  • Ursolic acid attenuates lipopolysaccharide-induced acute lung injury in a mouse model.

Ursolic acid attenuates lipopolysaccharide-induced acute lung injury in a mouse model.

Immunotherapy (2012-12-22)
Xiangjun Chen, Yang Wan, Taoyou Zhou, Jiong Li, Yuquan Wei
ABSTRACT

To assess whether ursolic acid (UA) can attenuate lipopolysachharide (LPS)-induced acute lung injury and improve the survival time in a mouse model. The mice were challenged with LPS and survival time was monitored from 0-96 h after LPS treatment. TNF-α, IL-6, IL-1β, HMGB1, nitric oxide (NO) and IL-10 concentration in serum were measured by ELISA. Myeloperoxidase activity, malondialdehyde, lung wet:dry weight ratio and lung permeability in lung tissues were detected. NF-κB, HMGB1 and inducible NO synthase in the lungs were detected by western blot. UA markedly rescued lethality, improved survival time and lung pathological changes, inhibited TNF-α, IL-6, IL-1β, HMGB1 and NO, and increased IL-10 expression. In addition, UA can also decrease myeloperoxidase, malondialdehyde, lung wet:dry weight ratio and lung permeability. UA attenuated NF-κB, HMGB1 and inducible NO synthase protein expression in the lungs. The results suggest that UA is capable of improving survival time and LPS-induced acute lung injury. UA has a potentially therapeutic role in septic shock.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ursolic acid, analytical standard
Sigma-Aldrich
Ursolic acid, ≥90%
Ursolic acid, primary reference standard